Self.co Raises €2.56M To Make Advanced Allergy Testing Accessible To Everyone

The €1.2 million investment round was led by Iron Wolf Capital, with participation from Coinvest, NGL Ventures, and several angel investors. In addition, Self.co received a €1.36 million grant from Innovation Agency Lithuania to advance its testing technology.

The newly secured funding will enable Self.co to expand into new markets and enhance its proprietary testing technology and long-term management tools. Allergies and intolerances currently affect between 30% and 40% of the global population a figure expected to rise to nearly 4 billion people by mid-century.

Despite this widespread impact, allergy diagnosis remains one of the most persistent gaps in healthcare. In the EU, around 45% of people with allergy-like symptoms are either misdiagnosed or never diagnosed at all. Many of these individuals mistake allergies for other immune or digestive issues, such as intolerances or sensitivities, resulting in years of uncertainty and ineffective treatment.

This challenge is further exacerbated by long waiting times often exceeding six months for specialist testing in public systems and high costs. Multiple intermediaries, low test throughput, and provider markups can push the price of a single molecular allergy test to between €200 and €400, making accurate diagnosis inaccessible to millions. As a result, people continue to suffer from fatigue, skin conditions or digestive problems without clear answers while healthcare systems bear billions in unnecessary costs each year.

Self.co addresses this issue through a holistic, science-based digital health platform. Its core offering consists of two proprietary microarray tests that detect 98 allergens and 220 food sensitivities from a simple blood sample collected either at home or through partner clinics. After professional lab evaluation, users receive a detailed avoidance plan and are connected to recommended supplements and treatments via Self.co’s network of healthcare partners.

Uniquely, Self.co is among the few companies globally producing molecular allergy tests with approximately 100 analytes. By managing every stage of the process from technology development to laboratory analysis and removing costly intermediaries, the company delivers laboratory-grade results for just €69–€99, a fraction of the traditional €200–€400 price.

According to Tautvydas Gylys, co-founder and CEO of Self.co, millions of people experience allergy-like symptoms without truly understanding their underlying causes or how to effectively address them.

“We've taken advanced diagnostic technology and built a simple test system that gives anyone clear, medically valid answers without the high cost or long wait.

Now the funding will help us bring our product to new markets like the UK, Ireland, Austria, and Germany, and deepen ongoing collaboration with healthcare systems in Poland and Lithuania."

Self.co’s testing technology, developed in collaboration with allergists and laboratory specialists, delivers molecular-level precision powered by microarray innovation. Advanced calibration techniques customize measurements for each allergen ensuring reliable accuracy even at the lowest concentrations. Highly sensitive fluorescence detection captures even the smallest immune responses while AI integrates clinical data with expert analysis to produce a personalized actionable report for every user.

Kasparas Jurgelionis, Managing Partner at Iron Wolf Capital, says: “As deep tech investors, we back technologies with the potential to transform established industries - and that’s exactly what Self.co is doing in allergy diagnostics and care. This is a large, fast-growing market still underserved by current solutions.

Tautvydas and the team combine exceptional industry insight with strong execution, giving them a rare founder-market fit.

Self.co’s platform addresses long-standing pain points for patients and clinicians, positioning the company to redefine allergy care globally.”

Self.co will use the new funding to build a digital health platform that helps people identify and manage allergy-like symptoms.

The platform will feature smart symptom questionnaires to better understand each person’s condition, offer a wider range of tests, and connect more closely with traditional healthcare services.

About Self.co

Self.co is a health tech company helping people uncover the real causes of their allergy-like symptoms through accurate, science-based home tests. By making advanced diagnostics affordable and accessible, Self.co empowers users with clear, personalized insights to improve their wellbeing.